Pharma CSRD
and PEPP reform 2026.
CSRD hits pharma + hospitals from fiscal year 2026 with full force. Plus: G-BA reform and PEPP adjustments fundamentally change valuation logic. We connect double materiality workshops, EU taxonomy application and regulatory depth into a 12-week DMA plan.
Three fractures in pharma/hospital reporting 2026
ESRS E2 (pollutants) for pharma
Pharma + hospital drug disposal are regulatorily captured (PFAS, antibiotic residues, cytostatics). Standard CSRD templates miss this - scope-3 category 12 (end-of-life processing) is 18-32% of hospital total balance. Naive accounting leads to limited assurance findings.
PEPP reform × OPS code change
G-BA decisions Q1-Q2 2026 change oncology + cardiology + specialty outpatient valuation. AMNOG procedure changes shift pharma pipeline pricing. Active M&A mandates need PEPP reform adjustment in every valuation - otherwise 12-22% overvaluation.
EU taxonomy in pharma
Eligibility + alignment for pharma research, medtech manufacturers, hospital operations is non-trivial. Greenwashing claims are the biggest reputation risk 2026-2028. Clean taxonomy balance reduces limited assurance risk and unlocks taxonomy-compliant refinancing (200-400 bp interest advantage).
ESRS application in healthcare - mandatory areas 2026
AME CSRD advisory DB - applications from 14 pharma + hospital mandates 2024-2026
| ESRS standard | Mandatory for | Hospital specifics | Pharma specifics |
|---|---|---|---|
| E1 Climate change | All CSRD-obliged | Hospital load profile + KHZG funding | Pharma production + cold-chain energy |
| E2 Pollution | MedTech + Pharma + Hospital | Drug disposal - anesthesia gases | PFAS - antibiotics - cytostatic residues |
| E3 Water | Pharma production | Hospital cooling - sterilization | API synthesis - water purity classes |
| E5 Circular economy | All healthcare | Single-use vs reuse - packaging | Pharma packaging - blister packs |
| S1 Workforce | All >250 employees | Care staff shortage - workload | Research personnel - diversity |
| G1 Compliance | All CSRD-obliged | §34d - GxP - KV compliance | GxP - AMNOG - EU MDR |
12-week DMA plan for pharma + hospitals
DMA setup (W 1-3)
Stakeholder mapping - IRO long-list - pre-materiality thresholds - workshop preparation - hospital/pharma sector templates activated.
DMA workshop (W 4-6)
Double materiality workshop - inside-out (impact) + outside-in (financial) - stakeholder engagement - IRO prioritization - ESRS mapping.
Data pipeline (W 7-9)
ESG data pipeline from hospital IT / pharma ERP - extend KHZG reporting interface - scope-3 supplier survey - anesthesia gas correction.
Reporting setup (W 10-12)
Limited assurance preparation - auditor interface (PwC/EY/KPMG/Mazars) - ESRS-structured reporting - EU taxonomy eligibility mapping.
Relevant tools for CSRD mandates
CO₂ Balance Calculator
Healthcare-specific scope 1+2+3 balance with anesthesia gas correction + pharma cold-chain
CSRD Quick-Check
Obligation check + DMA preparation - hospital/pharma-specific IRO long-list
Taxonomy Eligibility Tool
EU taxonomy eligibility for pharma research + medtech + hospital operations
Funding Navigator
ESG reporting investments - KHZG digital - BAFA energy audit
Healthcare-Mint × other AME clusters
Pharma/hospital CSRD mandates cross sectors. We connect:
DMA workshop - ESRS reporting - limited assurance - audit interface
CSRD status as DD factor - limited assurance findings as value driver/risk - ESG compliance in carve-out
Scope 1+2 reduction paths - KHZG micro-grid for hospital - pharma cold-chain optimization
Family-office ESG reporting for pharma holdings--§34d-compliant ESG reporting structuring
What role are you?
CSRD strategy varies per stakeholder:
Hospital CFO
ESRS mandatory mapping - DMA workshop - KHZG reporting integration
MVZ Leadership with group affiliation
Group CSRD obligation hits MVZ - data supply - ESG KPIs
Pharma Family
Pharma holdings CSRD - family-office ESG reporting--§34d connection
Care Investor
Care operator CSRD - portfolio ESG balance - S1 workforce
Common questions about pharma/hospital CSRD
Why AME STRATICON for pharma/hospital CSRD?
14 healthcare CSRD mandates since 2024
Hospital groups - pharma holdings - MVZ groups - medtech manufacturers - DMA templates proven
Sector depth + regulatory watch
Active G-BA decision monitoring - PEPP reform watch - AMNOG procedure updates - KHZG extension templates
Bertram + Marlies tandem
Bertram for healthcare M&A cross-sell + pharma sector strategy - Marlies for §34d family-office connection + pharma family reporting
Auditor interfaces
Practice interfaces to PwC, KPMG, EY, Deloitte, Mazars, BDO - limited assurance workflow templates per firm
Book pharma/hospital CSRD quick-check
30 minutes pre-briefing - DMA obligation clarification - sector-specific ESRS application - auditor recommendation.
Book pharma/hospital CSRD quick-check
Gemeinsam Ihr Energie-Portfolio in 60 Minuten sondieren.
Unter NDA. Wir schauen auf Ihre größten 3 Assets und nennen Ihnen die größten Hebel - kostenfrei. Yield-Modelle und Förder-Stack besprechen wir konkret.